DDInter1610 DDInter1352
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931]
Rivastigmine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Osimertinib
Rivastigmine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Osimertinib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Rivastigmine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is upregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Urinary retention
Urinary retention {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Osimertinib
Rivastigmine {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Riluzole
Riluzole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Bone disorder
Bone disorder {u} (Side Effect) is caused by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Rivastigmine {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Pimozide
Pimozide {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Transient ischaemic attack
Transient ischaemic attack {u} (Side Effect) is caused by {v} (Compound) Vandetanib
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Tetrabenazine
Tetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Rivastigmine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rivastigmine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rivastigmine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rivastigmine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is upregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rivastigmine (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rivastigmine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Riluzole (Compound) and Riluzole may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rivastigmine (Compound) causes Bone disorder (Side Effect) and Bone disorder (Side Effect) is caused by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rivastigmine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Pimozide (Compound) and Pimozide may lead to a major life threatening interaction when taken with Osimertinib
Rivastigmine (Compound) causes Transient ischaemic attack (Side Effect) and Transient ischaemic attack (Side Effect) is caused by Vandetanib (Compound) and Vandetanib may lead to a major life threatening interaction when taken with Osimertinib
Rivastigmine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound) and Tetrabenazine may lead to a major life threatening interaction when taken with Osimertinib